Gena Wang
Stock Analyst at Barclays
(2.17)
# 2,693
Out of 4,711 analysts
190
Total ratings
36.22%
Success rate
-2.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $509 → $418 | $397.27 | +5.22% | 15 | Dec 20, 2024 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $5 → $3 | $1.31 | +129.01% | 9 | Dec 13, 2024 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $45 → $56 | $46.24 | +21.11% | 14 | Dec 3, 2024 | |
| KOD Kodiak Sciences | Maintains: Underweight | $3 → $4 | $8.65 | -53.76% | 8 | Nov 15, 2024 | |
| BLUE bluebird bio | Maintains: Overweight | $80 → $40 | $8.50 | +370.59% | 9 | Nov 15, 2024 | |
| SGMO Sangamo Therapeutics | Maintains: Overweight | $3 → $9 | $2.47 | +264.37% | 3 | Nov 14, 2024 | |
| MRNA Moderna | Maintains: Overweight | $125 → $111 | $39.39 | +181.80% | 7 | Nov 8, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $76 → $55 | $12.18 | +351.56% | 6 | Nov 8, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $59 → $55 | $40.72 | +35.07% | 14 | Nov 6, 2024 | |
| CLLS Cellectis | Maintains: Overweight | $7 → $5 | $1.64 | +204.88% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $8 | $7.57 | +5.68% | 9 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $7.34 | +254.22% | 5 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $295 → $329 | $245.44 | +34.04% | 7 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $86 | $65.66 | +30.98% | 15 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $63 | $31.82 | +97.99% | 1 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $15 | $4.16 | +260.58% | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $226 → $203 | $118.97 | +70.63% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $33 → $31 | $29.01 | +6.86% | 8 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $50 | $7.62 | +556.17% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $81 | $44.22 | +83.18% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $51 | $35.63 | +43.14% | 9 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $6.31 | +613.15% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $94 | $34.08 | +175.82% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $14.14 | -36.35% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $15.48 | +61.50% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $6.15 | +192.68% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $8 | $6.73 | +18.87% | 1 | Nov 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $2.75 | +227.27% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $5.70 | +4,724.56% | 1 | Jan 6, 2017 |
Vertex Pharmaceuticals
Dec 20, 2024
Maintains: Equal-Weight
Price Target: $509 → $418
Current: $397.27
Upside: +5.22%
Editas Medicine
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $1.31
Upside: +129.01%
PTC Therapeutics
Dec 3, 2024
Maintains: Equal-Weight
Price Target: $45 → $56
Current: $46.24
Upside: +21.11%
Kodiak Sciences
Nov 15, 2024
Maintains: Underweight
Price Target: $3 → $4
Current: $8.65
Upside: -53.76%
bluebird bio
Nov 15, 2024
Maintains: Overweight
Price Target: $80 → $40
Current: $8.50
Upside: +370.59%
Sangamo Therapeutics
Nov 14, 2024
Maintains: Overweight
Price Target: $3 → $9
Current: $2.47
Upside: +264.37%
Moderna
Nov 8, 2024
Maintains: Overweight
Price Target: $125 → $111
Current: $39.39
Upside: +181.80%
Intellia Therapeutics
Nov 8, 2024
Maintains: Overweight
Price Target: $76 → $55
Current: $12.18
Upside: +351.56%
CRISPR Therapeutics AG
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $59 → $55
Current: $40.72
Upside: +35.07%
Cellectis
Nov 5, 2024
Maintains: Overweight
Price Target: $7 → $5
Current: $1.64
Upside: +204.88%
Nov 5, 2024
Maintains: Equal-Weight
Price Target: $7 → $8
Current: $7.57
Upside: +5.68%
Nov 4, 2024
Maintains: Overweight
Price Target: $28 → $26
Current: $7.34
Upside: +254.22%
Nov 1, 2024
Maintains: Overweight
Price Target: $295 → $329
Current: $245.44
Upside: +34.04%
Oct 4, 2024
Maintains: Overweight
Price Target: $110 → $86
Current: $65.66
Upside: +30.98%
Aug 28, 2024
Initiates: Overweight
Price Target: $63
Current: $31.82
Upside: +97.99%
Aug 14, 2024
Maintains: Overweight
Price Target: $18 → $15
Current: $4.16
Upside: +260.58%
Aug 8, 2024
Maintains: Overweight
Price Target: $226 → $203
Current: $118.97
Upside: +70.63%
Aug 7, 2024
Maintains: Equal-Weight
Price Target: $33 → $31
Current: $29.01
Upside: +6.86%
Aug 5, 2024
Maintains: Overweight
Price Target: $55 → $50
Current: $7.62
Upside: +556.17%
Aug 5, 2024
Maintains: Overweight
Price Target: $83 → $81
Current: $44.22
Upside: +83.18%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $45 → $51
Current: $35.63
Upside: +43.14%
Apr 15, 2024
Initiates: Overweight
Price Target: $45
Current: $6.31
Upside: +613.15%
Jan 24, 2024
Maintains: Overweight
Price Target: $93 → $94
Current: $34.08
Upside: +175.82%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $14.14
Upside: -36.35%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $15.48
Upside: +61.50%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $6.15
Upside: +192.68%
Nov 17, 2021
Maintains: Overweight
Price Target: $24 → $8
Current: $6.73
Upside: +18.87%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $2.75
Upside: +227.27%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $5.70
Upside: +4,724.56%